Liquidia Co. (NASDAQ:LQDA) General Counsel Sells $12,235.13 in Stock

Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler sold 1,063 shares of Liquidia stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $11.51, for a total value of $12,235.13. Following the completion of the transaction, the general counsel now owns 487,328 shares of the company’s stock, valued at $5,609,145.28. The trade was a 0.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Russell Schundler also recently made the following trade(s):

• On Monday, October 14th, Russell Schundler sold 2,576 shares of Liquidia stock. The shares were sold at an average price of $11.11, for a total value of $28,619.36.

Liquidia Stock Down 1.5 %

LQDA opened at $11.09 on Thursday. Liquidia Co. has a 52 week low of $6.83 and a 52 week high of $16.99. The business’s 50 day moving average is $10.80 and its two-hundred day moving average is $11.33.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on LQDA. Scotiabank began coverage on Liquidia in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price objective on shares of Liquidia in a research note on Thursday, November 14th. BTIG Research decreased their price objective on Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, August 19th. Bank of America decreased their target price on Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Tuesday, August 20th. Finally, HC Wainwright restated a “buy” rating and set a $29.00 target price on shares of Liquidia in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in LQDA. Whitefort Capital Management LP increased its position in Liquidia by 119.8% during the third quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock worth $17,020,000 after buying an additional 927,546 shares during the period. Charles Schwab Investment Management Inc. increased its position in Liquidia by 144.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock worth $3,903,000 after buying an additional 230,820 shares during the period. Anson Funds Management LP acquired a new position in Liquidia during the third quarter worth approximately $1,764,000. Sapient Capital LLC acquired a new position in Liquidia during the third quarter worth approximately $1,336,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of Liquidia by 735.1% in the third quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company’s stock valued at $1,402,000 after purchasing an additional 123,402 shares during the period. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).